Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.
J Neurol
January 2025
Second Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece.
Introduction: The current literature on the prevalence and potential association between disease-modifying therapies (DMTs) and cancer risk in the MS population has yielded mixed findings.
Methods: This study aimed to estimate cancer prevalence and cancer risk in patients with MS (PwMS) under prolonged DMT exposure. Database search include: MEDLINE PUBMED, SCOPUS, and Google Scholar.
Individual and sex differences in frontloading behavior and approach- avoidance conflict preference predict addiction-like ethanol seeking in rats.
Sci Rep
January 2025
Department of Psychology (Scarborough), University of Toronto, Toronto, ON, Canada.
Recent research has identified sex-dependent links between risk taking behaviors, approach-avoidance bias and alcohol intake. However, preclinical studies have typically assessed alcohol drinking using a singular dimension of intake (i.e.
View Article and Find Full Text PDFIdentification of potential biomarkers for 2022 Mpox virus infection: a transcriptomic network analysis and machine learning approach.
Sci Rep
January 2025
Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, 3114, Bangladesh.
Monkeypox virus (MPXV), a zoonotic pathogen, re-emerged in 2022 with the Clade IIb variant, raising global health concerns due to its unprecedented spread in non-endemic regions. Recent studies have shown that Clade IIb (2022 MPXV) is marked by unique genomic mutations and epidemiological behaviors, suggesting variations in host-virus interactions. This study aimed to identify the differentially expressed genes (DEGs) induced by the 2022 MPXV infection through comprehensive bioinformatics analyses of microarray and RNA-Seq datasets from post-infected cell types with different MPXV clades.
View Article and Find Full Text PDFPharmacokinetics of remimazolam, midazolam and diazepam in sheep.
Vet Anaesth Analg
December 2024
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA; Kenneth L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA.
Objective: To model pharmacokinetics of three benzodiazepines and their metabolites in sheep.
Study Design: A nonblinded, prospective, experimental study.
Animals: A group of six adult Hampshire-Suffolk cross-bred sheep (three females, three castrated males), 73 ± 3 kg (mean ± standard deviation).
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies.
J Immunother Cancer
January 2025
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
Background: ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.
Methods: In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!